AbbVie (ABBV) Stock Forecast & Price Target

AbbVie
Bull Case

Here are some ways that investors could benefit from investing in AbbVie Inc.:

• AbbVie Inc. recently reported third-quarter earnings that exceeded expectations, with revenue of $17.40 billion and an EPS of $3.82, beating the consensus estimate of $3.73. This performance, combined with a raised full-year adjusted earnings outlook, strengthens the growth case for the stock and demonstrates the company's ability to sustain revenue growth of 10.3% year-over-year.
• The company recently increased its quarterly dividend to $1.82, representing an annualized yield of approximately 2.5% based on recent pricing. This move signals management's confidence in cash flow generation and provides a steady income stream for investors, which is particularly attractive given the stock's defensive characteristics in the healthcare sector.
• Wall Street analysts have shown increasing optimism, with Wells Fargo raising its price target to $340.00 and Piper Sandler to $303.00 in recent months. The consensus rating remains a "Moderate Buy," and the average price target of $297.46 suggests that the current stock price of $292.87 still offers modest upside potential relative to analyst expectations.
• AbbVie Inc. is expanding its pipeline and research capabilities, including a global licensing deal with Nxera Pharma for an EP4 receptor agonist targeting inflammatory bowel disease and the establishment of a new research facility in Oxford, UK. These moves indicate a strategic focus on diversifying growth beyond its legacy products and investing in future therapeutic areas such as immunology and neuroscience.
• Institutional investor interest remains strong, with 70.23% of the stock owned by institutional investors and hedge funds. Recent filings show that funds like Allspring Global Investments Holdings LLC and Cullinan Associates Inc. increased their positions in the third quarter, suggesting that large capital allocators continue to view AbbVie Inc. as a core holding in their portfolios.